Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | PDE9A | O76083 | 4/20 | 0.32 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.32 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24971055 | 1.00 | KDM4E (0.32) | KDM4EPDE9APDE1BPDE5APDE4A | |
| SCHEMBL25754146 | 1.00 | KDM4E (0.32) | KDM4EPDE9APDE1BPDE5APDE4A | |
| SCHEMBL25754152 | 1.00 | KDM4E (0.32) | KDM4EPDE9APDE1BPDE5APDE4A | |
| SCHEMBL24973049 | 0.86 | PDE9A (0.33) | PDE9APDE1BPDE5APDE4APDE4B | |
| SCHEMBL25754156 | 0.86 | PDE9A (0.33) | PDE9APDE1BPDE5APDE4APDE4B | |
| SCHEMBL24973033 | 0.85 | PDE9A (0.31) | PDE9A | |
| SCHEMBL25754147 | 0.85 | PDE9A (0.31) | PDE9A | |
| SCHEMBL25754150 | 0.85 | PDE9A (0.31) | PDE9A | |
| SCHEMBL24973038 | 0.85 | PDE9A (0.31) | PDE9A | |
| SCHEMBL22327276 | 0.84 | KDM4E (0.47) | KDM4EPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-06-29 | — | — | US | disclosed |
| US-20230028359-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028359-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | KDM4E 4194/4885PDE9A 659/4885PDE1B 3649/4885 |
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | KDM4E 4194/4885PDE9A 659/4885PDE1B 3649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.